Equities

Keros Therapeutics Inc

KROS:NMQ

Keros Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)57.32
  • Today's Change1.61 / 2.89%
  • Shares traded393.95k
  • 1 Year change+63.07%
  • Beta1.1920
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Keros Therapeutics Inc have a median target of 88.00, with a high estimate of 105.00 and a low estimate of 76.00. The median estimate represents a 53.52% increase from the last price of 57.32.
High83.2%105.00
Med53.5%88.00
Low32.6%76.00

Earnings history & estimates in USD

On Aug 07, 2024, Keros Therapeutics Inc reported 2nd quarter 2024 losses of -1.25 per share. This result was in line with the consensus of the 10 analysts following the company and exceeded last year's 2nd quarter results by 1.57%.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+0.23%
Keros Therapeutics Inc reported annual 2023 losses of -5.20 per share on Feb 28, 2024.
Average growth rate-25.33%
More ▼

Revenue history & estimates in USD

Keros Therapeutics, Inc. had 2nd quarter 2024 revenues of 37.00k. None of the 10 analysts following the company expected it to generate revenues.
Average growth rate-32.46%
Keros Therapeutics, Inc. had revenues for the full year 2023 of 151.00k.
Average growth rate-100.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.